CYP2C19 genotype testing for clopidogrel: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI‐PGx)

Documenti analoghi

• ACKR1 /Duffy‐null genotype testing for clozapine: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI‐PGx)
  di: Stephen Murtough, et al.
  Pubblicazione: (2026)
• Health economic considerations for pharmacogenomic services in the United Kingdom: The Centre for Excellence in Regulatory Science and Innovation in Pharmacogenomics
  di: Dyfrig A. Hughes, et al.
  Pubblicazione: (2025)
• Limited Visibility and Perception of the Clinical Relevance of Clopidogrel Pharmacogenetics in Cardiology Literature
  di: Cinzia Dello Russo, et al.
  Pubblicazione: (2026)
• A Randomized Hybrid‐Effectiveness Trial Comparing Pharmacogenomics (PGx) to Standard Care: The PGx Applied to Chronic Pain Treatment in Primary Care (PGx‐ACT) Trial
  di: D. Max Smith, et al.
  Pubblicazione: (2025)
• CYP3A4*22 and bleeding risk in ticagrelor users
  di: Innocent G. Asiimwe, et al.
  Pubblicazione: (2024)